Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1152/ajprenal.00407.2014 http://scihub22266oqcxt.onion/10.1152/ajprenal.00407.2014 C4269693!4269693 !25298524     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25298524 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+J+Physiol+Renal+Physiol 2014 ; 307 (12 ): F1355-62 Nephropedia Template TP {{tp|p=25298524 |t=2014. Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension |pdf=|usr=}}{{25298524 }} gab.com Text Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension JO: Am J Physiol Renal Physiol http://www.kidney.de/pget.php?&tw=1&pmid=25298524 #FOAvip Recent findings suggest the therapeutic action of relaxin during hypertension is dependent on nitric oxide synthase (NOS) activation; however, the mechanisms underlying the beneficial effects of relaxin on the NOS system have not been fully elucidated. We hypothesized that the protective effects of relaxin include reducing both oxidative stress and the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA). We examined the effect of Serelaxin [human recombinant relaxin-2 (RLX)] in male Sprague-Dawley rats given high-dose angiotensin (ANG) II (400 ng·kg(-1)·min(-1) sc) for 6 wk or shams. RLX was administered (4 ?g/h sc) to half of the rats in each group after 2 wk of ANG II for the remaining 4 wk. ANG II induced hypertension and proteinuria, reduced NO oxidation products (NOx), and increased oxidative stress (NADPH oxidase activity, thiobarbituric acid-reactive substances, and 8-isoprostane excretion) and plasma ADMA. While RLX had no effect on sham rats, RLX attenuated the ANG II-dependent hypertension (165 ± 5 vs. 135 ± 13 mmHg, P < 0.05) and proteinuria at 6 wk (62 ± 6 vs. 41 ± 4 mg·day(-1)·100 g(-1), P < 0.05) and normalized oxidative stress and circulating ADMA, in association with restored NOx excretion and kidney cortex NOx. We found that RLX had no impact on the ADMA-regulatory enzymes protein arginine methyltransferase and dimethylarginine-dimethylaminohydrolase (DDAH). Furthermore, RLX treatment did not increase DDAH activity in kidney cortex or liver. These data suggest that benefits of RLX treatment include reduced ADMA levels and increased NO bioavailability, possibly due to its antioxidant effects. Twit Text FOAVip Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension ????Am J Physiol Renal Physiol http://www.kidney.de/pget.php?&tw=1&pmid=25298524 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25298524 #FOAvip English Wikipedia <ref>{{Cite pmid|25298524 }}</ref> Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension #MMPMID25298524 Sasser JM ; Cunningham MW Jr ; Baylis C Am J Physiol Renal Physiol 2014[Dec]; 307 (12 ): F1355-62 PMID25298524 show ga Recent findings suggest the therapeutic action of relaxin during hypertension is dependent on nitric oxide synthase (NOS) activation; however, the mechanisms underlying the beneficial effects of relaxin on the NOS system have not been fully elucidated. We hypothesized that the protective effects of relaxin include reducing both oxidative stress and the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA). We examined the effect of Serelaxin [human recombinant relaxin-2 (RLX)] in male Sprague-Dawley rats given high-dose angiotensin (ANG) II (400 ng·kg(-1)·min(-1) sc) for 6 wk or shams. RLX was administered (4 ?g/h sc) to half of the rats in each group after 2 wk of ANG II for the remaining 4 wk. ANG II induced hypertension and proteinuria, reduced NO oxidation products (NOx), and increased oxidative stress (NADPH oxidase activity, thiobarbituric acid-reactive substances, and 8-isoprostane excretion) and plasma ADMA. While RLX had no effect on sham rats, RLX attenuated the ANG II-dependent hypertension (165 ± 5 vs. 135 ± 13 mmHg, P < 0.05) and proteinuria at 6 wk (62 ± 6 vs. 41 ± 4 mg·day(-1)·100 g(-1), P < 0.05) and normalized oxidative stress and circulating ADMA, in association with restored NOx excretion and kidney cortex NOx. We found that RLX had no impact on the ADMA-regulatory enzymes protein arginine methyltransferase and dimethylarginine-dimethylaminohydrolase (DDAH). Furthermore, RLX treatment did not increase DDAH activity in kidney cortex or liver. These data suggest that benefits of RLX treatment include reduced ADMA levels and increased NO bioavailability, possibly due to its antioxidant effects. |*Angiotensin II [MESH] |Animals [MESH] |Antihypertensive Agents/administration & dosage/*pharmacology [MESH] |Antioxidants/administration & dosage/*pharmacology [MESH] |Arginine/*analogs & derivatives/blood [MESH] |Arterial Pressure/drug effects [MESH] |Dinoprost/analogs & derivatives/metabolism [MESH] |Disease Models, Animal [MESH] |Down-Regulation [MESH] |Humans [MESH] |Hypertension/blood/chemically induced/physiopathology/*prevention & control [MESH] |Injections, Subcutaneous [MESH] |Kidney/drug effects/metabolism [MESH] |Liver/drug effects/metabolism [MESH] |Male [MESH] |NADPH Oxidases/metabolism [MESH] |Nitric Oxide/metabolism [MESH] |Oxidative Stress/*drug effects [MESH] |Proteinuria/chemically induced/metabolism/prevention & control [MESH] |Rats, Sprague-Dawley [MESH] |Recombinant Proteins/administration & dosage/pharmacology [MESH] |Relaxin/administration & dosage/*pharmacology [MESH]Serelaxin reduces oxidative stress and asymmetric dimethylarginine in (epmc).pdf DeepDyve Pubget Overpricing